Metastatic potential and prognostic significance of SOX2: A meta-analysis.
Cancer
Cancer stem cell markers
Lymphatic metastasis
SOX2
Tumor progression
Journal
World journal of clinical oncology
ISSN: 2218-4333
Titre abrégé: World J Clin Oncol
Pays: United States
ID NLM: 101549149
Informations de publication
Date de publication:
24 Jun 2019
24 Jun 2019
Historique:
received:
21
01
2019
revised:
31
03
2019
accepted:
08
04
2019
entrez:
2
8
2019
pubmed:
2
8
2019
medline:
2
8
2019
Statut:
ppublish
Résumé
SOX2 is a regulator of pluripotent cellular transcription, yet it has been recently integrated in cancer biology. The present study provides an analytic insight into the correlation of SOX2 overexpression with cancer metastasis and patient survival. To investigate the association of SOX2 overexpression with metastasis and its implication in the prognosis of cancer patients. A meta-analysis was conducted including studies that compared the association of low or high SOX2 expression with lymph node metastasis (LNM) and/or distant metastasis (DM). The following data were additionally extracted: survival, including the overall survival (OS) and disease-free survival (DFS), and prevalence of high and low SOX2 expression. Odds ratios (commonly known as ORs) and their respective 95% confidence intervals (CIs) were used to investigate the association between SOX2 expression and LNM and DM, while hazard ratios (commonly known as HRs) and 95%CIs were applied to evaluate the prognostic markers. In a total of 2643 patients (60.88% males), the pooled prevalence of SOX2 overexpression was 46.22% (95%CI: 39.07%-53.38%) in different types of cancer. SOX2 overexpression significantly correlated with DM (OR = 1.79, 95%CI: 1.20-3.25, A remarkable role of SOX2 overexpression was observed in cancer biology and metastasis. However, many questions in the regulatory pathways need to be addressed to reveal as many functional aspects as possible to tailor new targeted therapeutic strategies.
Sections du résumé
BACKGROUND
BACKGROUND
SOX2 is a regulator of pluripotent cellular transcription, yet it has been recently integrated in cancer biology. The present study provides an analytic insight into the correlation of SOX2 overexpression with cancer metastasis and patient survival.
AIM
OBJECTIVE
To investigate the association of SOX2 overexpression with metastasis and its implication in the prognosis of cancer patients.
METHODS
METHODS
A meta-analysis was conducted including studies that compared the association of low or high SOX2 expression with lymph node metastasis (LNM) and/or distant metastasis (DM). The following data were additionally extracted: survival, including the overall survival (OS) and disease-free survival (DFS), and prevalence of high and low SOX2 expression. Odds ratios (commonly known as ORs) and their respective 95% confidence intervals (CIs) were used to investigate the association between SOX2 expression and LNM and DM, while hazard ratios (commonly known as HRs) and 95%CIs were applied to evaluate the prognostic markers.
RESULTS
RESULTS
In a total of 2643 patients (60.88% males), the pooled prevalence of SOX2 overexpression was 46.22% (95%CI: 39.07%-53.38%) in different types of cancer. SOX2 overexpression significantly correlated with DM (OR = 1.79, 95%CI: 1.20-3.25,
CONCLUSION
CONCLUSIONS
A remarkable role of SOX2 overexpression was observed in cancer biology and metastasis. However, many questions in the regulatory pathways need to be addressed to reveal as many functional aspects as possible to tailor new targeted therapeutic strategies.
Identifiants
pubmed: 31367532
doi: 10.5306/wjco.v10.i6.234
pmc: PMC6657218
doi:
Types de publication
Journal Article
Langues
eng
Pagination
234-246Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare no conflicts of interest.
Références
Hum Mol Genet. 2006 May 1;15(9):1413-22
pubmed: 16543359
Cancer Metastasis Rev. 2006 Mar;25(1):9-34
pubmed: 16680569
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Br J Cancer. 2008 Feb 26;98(4):824-31
pubmed: 18268498
Cell Mol Life Sci. 2008 Oct;65(19):3000-18
pubmed: 18516494
Stem Cells. 2009 Jan;27(1):40-8
pubmed: 18948646
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
J Gastrointest Surg. 2010 Aug;14(8):1220-6
pubmed: 20532662
Onco Targets Ther. 2010 Jun 24;3:83-97
pubmed: 20616959
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
J Transl Med. 2010 Oct 12;8:94
pubmed: 20937145
J Surg Res. 2012 May 1;174(1):130-5
pubmed: 21227461
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Mol Cell Biol. 2011 Aug;3(4):230-8
pubmed: 21415100
Mol Cell Biochem. 2011 Sep;355(1-2):173-8
pubmed: 21541674
Oncol Rep. 2011 Nov;26(5):1069-74
pubmed: 21811761
PLoS One. 2011;6(11):e26740
pubmed: 22069467
BMC Cancer. 2011 Dec 14;11:518
pubmed: 22168803
Lab Invest. 2012 Mar;92(3):362-70
pubmed: 22184093
PLoS One. 2012;7(8):e41335
pubmed: 22912670
Crit Rev Oncog. 2013;18(1-2):43-73
pubmed: 23237552
PLoS One. 2013;8(2):e56324
pubmed: 23424657
Med Oncol. 2013 Jun;30(2):503
pubmed: 23430442
Auris Nasus Larynx. 2013 Oct;40(5):481-6
pubmed: 23462687
Oncogenesis. 2013 Aug 05;2:e61
pubmed: 23917223
Clin Breast Cancer. 2014 Feb;14(1):e1-9
pubmed: 24201161
Int J Clin Exp Pathol. 2013 Nov 15;6(12):2846-54
pubmed: 24294370
Int J Cancer. 2014 Aug 15;135(4):809-19
pubmed: 24477565
Hum Pathol. 2014 Apr;45(4):851-7
pubmed: 24656096
Oncol Rep. 2014 Jun;31(6):2651-9
pubmed: 24700142
J Histochem Cytochem. 2014 Jul;62(7):499-509
pubmed: 24710660
Carcinogenesis. 2014 Jul;35(7):1636-42
pubmed: 24743512
Int J Mol Sci. 2014 May 13;15(5):8393-406
pubmed: 24828201
PLoS One. 2014 Jun 17;9(6):e99594
pubmed: 24937695
Cancer Lett. 2015 Mar 28;358(2):210-219
pubmed: 25543086
PLoS One. 2015 Mar 13;10(3):e0118961
pubmed: 25768737
Int J Mol Sci. 2015 Sep 08;16(9):21643-57
pubmed: 26370982
Int J Clin Exp Pathol. 2015 Aug 01;8(8):9248-55
pubmed: 26464673
Oncol Lett. 2016 Feb;11(2):1435-1446
pubmed: 26893757
J Cancer Res Clin Oncol. 2016 Jun;142(6):1221-30
pubmed: 26960758
Genes Dev. 2016 Apr 15;30(8):892-908
pubmed: 27083997
Oncotarget. 2016 Sep 20;7(38):62049-62069
pubmed: 27557490
Biochim Biophys Acta Mol Basis Dis. 2017 Jan;1863(1):253-265
pubmed: 27816521
Lab Invest. 2017 Feb 27;:null
pubmed: 28240746
Mol Med Rep. 2017 Apr;15(4):1693-1701
pubmed: 28259951
Am J Transl Res. 2018 Feb 15;10(2):639-647
pubmed: 29511458
PLoS One. 2018 Mar 29;13(3):e0194989
pubmed: 29596469
Int J Mol Med. 2018 Sep;42(3):1418-1426
pubmed: 29956740
Front Pharmacol. 2018 Aug 21;9:942
pubmed: 30186173
Onco Targets Ther. 2018 Aug 24;11:5171-5181
pubmed: 30210237
Mamm Genome. 1994 Oct;5(10):640-2
pubmed: 7849401